VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Verrica Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.44−0.16 (-4.31%)
Close on Oct 19, 2026
- Market cap
- $73.29M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.71 (−17.11%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Verrica Pharmaceuticals Inc. grew revenue 106.2% to $30.32M over the twelve months to Jun 30, 2026. Free cash flow was -$17.63M.
Revenue
$30.32M
+106.2% vs. a year earlier
Operating income
-$28.38M
TTM Q2 2026
Free cash flow
-$17.63M
FY2025
EPS, diluted
-$1.67
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $73.29M
- P/E ratio
- –
- Price to sales
- 2.42
- Price to book
- 17.02
- Dividend yield
- –
- Free cash flow yield
- -24.05%
Fundamentals
- Revenue
- $30.32M
- Net income
- -$31.18M
- EPS, diluted
- -$1.67
- Free cash flow
- -$17.63M
- Book value per share
- $0.20
- Diluted shares
- 21M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$30.32M+106.2% YoY
Gross profit
–
Operating income
-$28.38M
Net income
-$31.18M
EPS, diluted
-$1.67
Free cash flow
–
Reported periodTrailing twelve months